Ewing sarcoma in adolescents and young adults: diagnosis and treatment

Lara E Davis1,2
Suman Malempati2
1Department of Medicine, 2Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA

Abstract: Ewing sarcoma (ES) is a rare tumor that most often occurs in adolescents and young adults. This review discusses the diagnosis, prognosis, and treatment of localized and metastatic ES, with an emphasis on the care of adolescent and young adult patients. The pathobiology is reviewed. Particular attention is given to recent and current clinical trials, and an introduction to future directions for therapy of ES is provided.

Keywords: Ewing, sarcoma, primitive neuroectodermal tumor, PNET

Introduction

The Ewing sarcoma family of tumors (ESFTs) includes small, round, blue cell tumors with a characteristic translocation involving EWS and an ETS-family gene, most frequently FLI1. These tumors include ES of bone, extraskeletal ES, peripheral primitive neuroectodermal tumors (PNET), and Askin’s tumors (PNET of the chest wall).

Epidemiology

Approximately 50% of ESFTs occur in adolescents and young adults (AYAs).1 ES is uncommon, however, and thus accounts for less than 5% of the malignancies diagnosed in AYA patients.1 The peak incidence of ES occurs between 10 and 20 years of age, and ES is rare over the age of 30 years.2

Among persons 15–29 years old, there are approximately 260 ESs diagnosed each year in the US.1 Surveillance, Epidemiology, and End Results data indicate that within adolescents 15–19 years old, males are nearly twice as likely to be diagnosed with ES than females, and Caucasian teens develop ES 18 times more frequently than African Americans (Figure 1).3 These statistics are consistent worldwide, including the rarity of ES in black populations.4 The reason for the relatively low incidence of ES in black populations is unknown.

Clinical presentation

ES typically presents as a rapidly growing mass that is often painful. The long bones are the most common primary sites, although the bones of the axial skeleton are also frequently involved, particularly in older patients. ES can arise anywhere in the body, and up to 20% of cases are extraskeletal.2

Typical radiographic characteristics of aggressive bone malignancies are seen in ES, including a permeative pattern of bony destruction, often through the marrow space and/or with an associated soft-tissue mass. The classic appearance of lamellate or “onion
A skin” periosteal reaction is frequently seen on radiography, and represents the layering of new bone surrounding a region of malignant cortical destruction (Figure 2).

Staging

Approximately 20%–25% of patients will have metastatic disease detected at initial diagnosis.5–7 Of those patients with primary metastatic disease, an equal percentage present with metastases limited to the lungs versus limited to bones and/or bone marrow (approximately 40% each), while an additional 20% have disease in multiple distant sites.7 Therefore, at a minimum, initial staging workup should include radiographs and magnetic resonance imaging of the primary site, as well as computed tomography of the chest and a whole-body bone scan. 18F-fluorodeoxyglucose positron-emission tomography may be considered, but is not universally recommended. Staging of ES follows the TNM (tumor, nodes, metastasis) system for bone tumors.8 However, apart from metastatic versus localized disease, the disease stage is not clinically relevant for prognosis or treatment.

Diagnosis

The diagnoses of typical ES, extraskeletal ES, and PNET were not widely recognized to be a single pathologic entity until the early 2000s, at which point genomic data supported the grouping of all EWS-ETS-driven tumors together.

Histology and immunohistochemistry

The diagnosis of ES can often be made by core needle biopsy, although open biopsy may be necessary in atypical cases. ESFTs are high-grade tumors by definition.2 Historically, the term PNET was used for tumors with histologic features of neuroectodermal differentiation, while the term ES was applied to tumors lacking such differentiation.1,2 Typical ES has a homogeneous appearance with sheets of small round blue cells, and may contain variable amounts of necrosis (Figure 3). PNETs may have the additional finding of rosettes or pseudorosettes, indicative of neural differentiation.2 Atypical ES includes histologic variants, such as those with significant cellular and nuclear pleomorphism or hemangioendothelial features.9

The vast majority of ESFTs are CD99-positive, predominantly in a membranous pattern, but cytoplasmic

Figure 1 Incidence of Ewing sarcoma within the adolescent and young adult population, 2004–2008.
Note: Adapted from Howlader et al.8

Figure 2 (A–E) Radiologic appearance of Ewing sarcomas.
Notes: (A) Ewing sarcoma of the humerus on plain radiograph demonstrates classic findings of permeative bone destruction, lamellate new bone formation, and Codman triangle, best seen on magnification (B). Extraskeletal Ewing sarcomas may have normal radiographs, but an enhancing soft-tissue mass will be apparent on magnetic resonance imaging, as in these sagittal (C), axial (D), and coronal (E) T1 fat-saturated postcontrast images of an extraskeletal Ewing sarcoma of the hand. Images courtesy of Dr Donald Sauser.
positivity may also be present. In cases where additional immunohistochemistry confirmation is needed, positive nuclear Fli1 or cytoplasmic and nuclear caveolin 1 expression may be helpful. However, these are rarely used in practice, since disruption of EWSR1 can be readily identified by fluorescence in situ hybridization.9

**Translocation**

The ESFTs are defined by a characteristic translocation involving the central exons of the EWSR1 gene on chromosome 22 and the central exons of an ETS-family gene. There are 29 members of the ETS (E26 transformation-specific) family of transcription factors, which are proto-oncogenes as a result of their important roles in cell-cycle control. A tumorigenic fusion protein forms when one of these transcription factors is aberrantly under the control of a transcription activation domain from within the EWS gene.

Approximately 85% of ESs result from t(11;22), which produces the EWSR1-FLI1 oncoprotein.2 While translocations with FLI1 are most common, an additional 10% of ESFTs are associated with a translocation with ERG on chromosome 21.10,11 Alternative proto-oncogene fusion partners include ETV1, ETV4 (EIAF), and FEV, among others.12–14 The specific translocation or fusion type is no longer thought to have prognostic significance.15

By itself, lack of molecular confirmation of EWSR1 rearrangement does not rule out a diagnosis of ES. Rearrangements of other TET-family genes may also result in ES, and there is a growing body of literature on “Ewing-like” sarcomas that harbor translocations between TET-family genes and non-ETS genes, or non-TET genes and ETS-family genes.2 A summary of chromosomal rearrangements found in ES and Ewing-like sarcoma is shown in Table 1.

**Prognosis**

The presence or absence of metastatic disease is the single most powerful predictor of outcome in ES.3 Event-free survival (EFS) at 5 years is greater than 70% for patients with localized disease, but has stagnated at 30% for patients with primary metastatic disease.7,16–18 Among those with metastases, better prognosis is associated with metastases confined to the lung; patients with unilateral pulmonary metastases do better still.5,7,19,20

While risk stratification of ES has not entered into routine treatment decisions, high-risk localized disease is generally defined as any pelvic tumor, tumors that cannot achieve complete local control (details in the “Treatment” section), or large tumors with poor histologic response to preoperative therapy.

The primary tumor site and size are well-recognized prognostic factors. In general, more distal tumors predict complete local control (details in the “Treatment” section), or large tumors with poor histologic response to preoperative therapy.

**Table 1** Chromosomal rearrangements found in Ewing sarcoma and “Ewing-like” sarcoma

<table>
<thead>
<tr>
<th>Translocation</th>
<th>Fusion gene</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>t(11;22)(q24;q12)</td>
<td>EWSR1–FLI1</td>
<td>Turc-Carel et al10</td>
</tr>
<tr>
<td>t(21;22)(q22;q12)</td>
<td>EWSR1–ERG</td>
<td>Sorensen et al11</td>
</tr>
<tr>
<td>t(7;22)(q22;q12)</td>
<td>EWSR1–ETV1</td>
<td>Jeon et al12</td>
</tr>
<tr>
<td>t(17;22)(q11;q12)</td>
<td>EWSR1–ETV4</td>
<td>Kaneko et al13, Urano et al14</td>
</tr>
<tr>
<td>t(22;22)(q35;q12)</td>
<td>EWSR1–FEV</td>
<td>Peter et al15</td>
</tr>
<tr>
<td>t(16;21)(p11;q22)</td>
<td>FUS–ERG</td>
<td>Shing et al16</td>
</tr>
<tr>
<td>t(2;16)(q35;p11)</td>
<td>FUS–FEV</td>
<td>Ng et al17</td>
</tr>
<tr>
<td>t(20;22)(q13;q12)</td>
<td>EWSR1–NFIATC2</td>
<td>Szuha et al18</td>
</tr>
<tr>
<td>t(6;22)(p21;q12)</td>
<td>EWSR1–POUSF1</td>
<td>Yamaguchi et al19</td>
</tr>
<tr>
<td>t(4;22)(q31;q12)</td>
<td>EWSR1–SMARC5</td>
<td>Sumegi et al20</td>
</tr>
<tr>
<td>Submicroscopic inv(22) in t(1;22)</td>
<td>EWSR1–PATZ</td>
<td>Mastrangelo et al21</td>
</tr>
<tr>
<td>(p36.1;q12)</td>
<td>EWSR1–SP3</td>
<td>Wang et al22</td>
</tr>
<tr>
<td>t(22;22)(q31;q12)</td>
<td>GIX–DUX4</td>
<td>Kawamura-Saito et al23</td>
</tr>
<tr>
<td>t(4;19)(q35;q13)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: “Can occur in ring chromosome and may be amplified. Copyright © 2014 World Health Organization. Reproduced with the permission of World Health Organization from WHO Classification of Tumours of Soft Tissue and Bone, Geneva, World Health Organization, 2013 (Table 19.01, page 307, Chromosomal rearrangements found in Ewing sarcoma and “Ewing-like” sarcoma).
better outcomes compared to tumors located more centrally. Pelvic and sacral ES have the worst outcomes, with 5-year EFS approximately 50%. Larger tumors, generally defined as those ≥8 cm (or 200 mL in volume), portend a similar reduction in EFS.

Response to preoperative chemotherapy is also strongly predictive of disease-free survival. Patients with <5% viable tumor at the time of resection are dramatically more likely to be disease-free after 5 years compared to patients with ≥30% viable tumor (disease-free survival 75% versus 20%, P<0.001).

In addition, older age is a negative prognostic indicator. Young children have the best outcomes, while adults over the age of 40 years fare the worst. A summary of outcomes by age reported in both prospective and retrospective studies is provided in Table 2.

Finally, patients with recurrent disease have a dismal prognosis. Of the 30%–40% of patients with disease relapse after initial treatment, less than 20% will survive 5 years following recurrence. Longer survival may be seen in relapsed patients with favorable features, such as limited local recurrence or recurrence occurring more than 2 years after initial diagnosis.

## Treatment
Patients with ESFTs should be evaluated and treated at a sarcoma center with multidisciplinary expertise. The importance of diagnosis and treatment by a multidisciplinary team is noted within the National Comprehensive Cancer Network Guidelines, among others.

### Localized disease

The current standard of care in North America for localized ES was established by large cooperative clinical trials completed in the 1990s and early 2000s. In the landmark Intergroup (INT)-0091 trial, the addition of ifosfamide and etoposide (IE) to a backbone of vincristine, doxorubicin, and cyclophosphamide (VDC) improved overall survival (OS) among patients without metastases from 61% to 72% (P=0.01), and EFS improved from 54% to 69% (P=0.005, Figure 4). The standard of care was further refined by alternating IE with VDC every 2 weeks rather than every 3 weeks (termed interval compression or dose-dense) following completion of the Children’s Oncology Group (COG) trial AEWS0031. In this trial, interval compression improved 5-year EFS from 65% to 73% (P=0.05), and showed a trend toward improvement in OS (77% versus 83%, P=0.06, Figure 5A and B).

The majority of patients in these trials were pediatric, but patients over the age of 18 years were eligible. Patients 18 years or older enrolled in AEWS0031 (n=67) experienced a considerably worse EFS of 47% versus 72% at 5 years (P<0.001, Figure 5C).

### Table 2 Outcomes by age for localized Ewing sarcoma

<table>
<thead>
<tr>
<th>Reference</th>
<th>Systemic agents</th>
<th>Pediatric ages, years</th>
<th>Pediatric outcome</th>
<th>Adult ages, years</th>
<th>Adult outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rosito et al</td>
<td>SE-91 CNR: VACA-IE</td>
<td>&lt;14</td>
<td>3-year EFS 85%</td>
<td>≥15</td>
<td>3-year EFS 71%</td>
</tr>
<tr>
<td>Paulussen et al</td>
<td>CESS-86: VACA or VAIA</td>
<td>≥15</td>
<td>10-year EFS 53% (NS)</td>
<td>&gt;15</td>
<td>10-year EFS 49% (NS)</td>
</tr>
<tr>
<td>Grier et al</td>
<td>INT-0091: VACA or VACA-IE</td>
<td>&lt;10-17</td>
<td>5-year EFS 70%</td>
<td>≥18</td>
<td>5-year EFS 44%</td>
</tr>
<tr>
<td>Obata et al</td>
<td>Varied</td>
<td>&lt;16</td>
<td>5-year EFS 50%</td>
<td>≥16</td>
<td>5-year EFS 31%</td>
</tr>
<tr>
<td>Pieper et al</td>
<td>As per EICESS 92 or Euro-EWING 99</td>
<td>NA</td>
<td>NA</td>
<td>&gt;40</td>
<td>3-year EFS 50%*</td>
</tr>
<tr>
<td>Granowetter et al</td>
<td>VDC/IE</td>
<td>&lt;10</td>
<td>5-year EFS 78%</td>
<td>≥18</td>
<td>5-year EFS 63%</td>
</tr>
<tr>
<td>Gupta et al</td>
<td>VDC/IE**</td>
<td>&lt;16</td>
<td>3-year EFS 70% (NS)</td>
<td>≥16</td>
<td>3-year EFS 43% (NS)</td>
</tr>
<tr>
<td>Ferrari et al</td>
<td>VACA/IE ± HDC + auto-SCT</td>
<td>&lt;10-17</td>
<td>5-year EFS 77%</td>
<td>≥18</td>
<td>5-year EFS 62%</td>
</tr>
<tr>
<td>Womer et al</td>
<td>VDC/IE</td>
<td>&lt;10</td>
<td>5-year EFS 72%***</td>
<td>≥18</td>
<td>5-year EFS 47%</td>
</tr>
<tr>
<td>Ahmed et al</td>
<td>Varied; 54% received VDC/IE</td>
<td>NA</td>
<td>NA</td>
<td>≥18</td>
<td>5-year EFS 52% (NS)</td>
</tr>
</tbody>
</table>

Notes: *Includes 13 patients with metastatic disease at diagnosis; **statistically different median number of cycles delivered between pediatrics and adults (16 versus 10, P=0.0001); ***EFS for <10 years versus 10–17 years not reported. Difference in outcomes statistically significant (P<0.05) unless otherwise noted.

Abbreviations: CNR, National Council of Research (Italy); INT, Intergroup; EICESS, European Intergroup Cooperative Ewing Sarcoma Study; EWING, Ewing tumour Working Initiative of National Groups; EFS, event-free survival; VACA, vincristine, actinomycin, cyclophosphamide, doxorubicin; IE, ifosfamide, etoposide; VAIA, vincristine, actinomycin, ifosfamide, doxorubicin; VDC, vincristine, doxorubicin, cyclophosphamide; HDC, high-dose chemotherapy; auto-SCT, autologous stem cell transplant; NS, not significant (P>0.05); NA, not applicable; OS, overall survival.
such that pediatric patients with pelvic tumors had equivalent outcomes to adult patients with nonpelvic primaries. A single-institution retrospective analysis of patients with localized, nonpelvic ES treated within the adult cancer center (generally patients >16 years old) compared to children treated within the affiliated pediatric center, found a significant difference in 3-year OS of 67% versus 88% (P=0.04). However, similar analyses at a different institution found 5-year OS and EFS among adult patients to be comparable to those achieved in INT-0091, and a retrospective subset analysis from two modern European cooperative group trials suggests that adults over the age of 40 years can have similar outcomes to adolescents when treated in strict accordance with a pediatric protocol. Taken together, these data suggest that with contemporary supportive care, adults with localized, nonpelvic primary tumors may achieve outcomes similar to children if treated with interval-compressed multidrug regimens and aggressive local control measures (Table 2).

Local control with surgery and/or radiation is paramount. Whether surgery achieves better local control than radiation therapy alone is controversial, but in practice, surgery is generally preferred when possible due to the known late effects of radiation. Local control is generally undertaken after 12 weeks of “induction” chemotherapy with VDC/IE. For residual disease following surgical resection, postoperative radiation to 45–50.4 Gy is recommended, and can be administered concurrently with IE, preferably beginning within 2 weeks (and not more than 6 weeks) of resection. ESs are very radiosensitive, and radiation should always be

Figure 4 Results of the Intergroup (INT)-0091 trial of four-drug versus six-drug chemotherapy regimens: event-free survival according to study group and the presence or absence of metastatic disease.


Figure 5 (A–D) Results of the Children’s Oncology Group AEWS0031 trial of interval compression.

Notes: Reprinted with permission. Copyright © 2012 American Society of Clinical Oncology. All rights reserved. Womer RB, West DC, Krailo MD, et al. Randomized Controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(33):4148–4154. (A) Event-free survival (EFS) and (B) overall survival (OS), according to the assigned treatment regimen of standard (chemotherapy every 3 weeks) versus intensive (chemotherapy every 2 weeks). (C) EFS and (D) OS, respectively, stratified by age and site of primary tumor, combining the treatment regimens.
employed when complete surgical resection is not feasible. In these cases, definitive radiation therapy to a dose of 45 Gy to the tumor bed is recommended, with an additional 10.8 Gy to a surrounding margin of 1.5 cm minimum.16

**Metastatic disease**

There is no broadly accepted standard of care for metastatic ES, and numerous treatment regimens are actively being investigated (see the “Future directions” section). All patients with metastatic ES should be offered enrollment in a clinical trial.

Nonetheless, there is evidence that the intensification approaches taken for localized disease do not benefit those with metastases. The INT-0091 trial demonstrated that there is no benefit to the addition of IE to the standard three-drug regimen of VDC for patients with metastatic disease (Figure 4).17 There is also no evidence that interval compression improves outcomes, except in patients with localized disease.16 Therefore, outside a clinical trial, a frontline regimen of VDC every 3 weeks is reasonable for these patients.

Various multichemotherapy regimens for relapsed and refractory ES are well represented in the literature in retrospective institutional experiences or small clinical trials. Irinotecan and temozolomide (with or without vincristine) or cyclophosphamide and topotecan administered for 5 days every 3 weeks are reasonable outpatient regimens with published efficacy and tolerability.34–37 Treatment with numerous additional systemic agents and regimens have been reported, including the synthetic alkaloid PM00104, VEGFR inhibitors, or gemcitabine/docetaxel, but none has demonstrated sufficient improved efficacy or reduced toxicity sufficient to supplant the current standards of care.38–40

For patients with lung metastases, whole-lung irradiation is sometimes employed, although prospective data are lacking.7,26,41 There are data to support aggressive local treatment of metastatic sites (surgical resection or radiotherapy) when possible.42,43 High-dose chemotherapy followed by autologous stem cell transplantation (SCT) has been investigated repeatedly, but remains controversial. The results of numerous studies are mixed, and there is no consensus that this therapy provides benefit, given the biases inherent in the studies published to date.44–46 There is therefore insufficient evidence currently to support treatment with autologous transplant outside a clinical trial. Allogeneic transplant has been used rarely, although there are isolated reports of long-term survivors of metastatic ES using this approach.47–49

**The Euro-EWING (Ewing tumour working initiative of national groups)-99 trial** (described in the “Current clinical trials” section) attempts to resolve the debates over whole lung irradiation and autologous SCT in metastatic ES definitively, but results are not yet available.

**Surveillance**

Upon completion of curative-intent chemotherapy, the COG recommends radiographs of the primary site, plus chest computed tomography and a whole-body bone scan. Follow-up radiographs of chest and the primary site are recommended for the subsequent 10 years, initially every 3 months, then decreasing in frequency steadily to annually for the final 5 years.50 ES has the potential to recur several years after initial remission.17,51 Therefore, prolonged surveillance for recurrent disease is necessary.

Survivors of ES require ongoing long-term follow-up care to monitor for late effects of therapy. Historically, patients with ES were among the most likely to develop a treatment-related second malignancy, often sarcomas.52 A large percentage of these cancers were likely radiation-associated, and as local treatment has shifted towards surgery, the long-term effects of systemic therapy are becoming more prominent. A patient treated with the standard interval-compressed five-drug regimen for localized ES will have received cumulative doses totaling doxorubicin 375 mg/m², cyclophosphamide 10.8 g/m², ifosfamide 72 g/m², etoposide 4,000 mg/m², and 18 doses of vincristine. Secondary myeloid dysplasia/neoplasia is a concern, as are early coronary artery disease, infertility, renal dysfunction, and neuropathy. Cumulative mortality among ES survivors is 25% at 25 years after diagnosis, and survivors have a markedly increased risk of severe, life-threatening, or disabling health conditions (relative risk 6.0) compared to siblings.53

**Future directions**

Refinements to interval-compressed five-drug chemotherapy are expected, but novel treatment approaches targeting the pathogenic molecular pathways underlying ES will be moving into the clinic in the foreseeable future as well. In order for these advances to positively impact outcomes for AYAs, it is imperative that ES patients of all ages are enrolled in clinical trials and biospecimen banking. There has been a push in recent years to open clinical trial enrollment for “pediatric” diseases to AYA-aged patients. As a result, AYAs (including up to and sometimes beyond age 40 years) are eligible for the majority of current ES clinical trials and biology studies.
Current clinical trials

The COG and Spain’s Grupo Español de Investigación en Sarcomas (GEIS) have large, multi-institutional ES trials ongoing, investigating alternative cytotoxic regimens for localized disease (NCT01231906, NCT01696669). The GEIS study incorporates gemcitabine and docetaxel for high-risk patients, defined as patients with primary tumors of the axial skeleton. The COG AEWS1031 study is comparing standard interval-compressed VDC/IE with a similar regimen incorporating topotecan, based on the efficacy of topotecan in the relapsed and metastatic setting.35,54

The poor clinical outcomes for patients with metastatic disease have stimulated numerous investigations into new ways to use old treatments, as well as novel treatments. The current largest effort is directed at high-dose chemotherapy with autologous SCT. This strategy has been investigated in small series for decades, but the large prospective Euro-EWING-99 trial (NCT00020566) is incorporating SCT for high-risk disease. Euro-EWING-99 is a complex international trial that enrolled patients into four separate, risk-stratified cohorts: nonmetastatic with good histologic response to induction chemotherapy, nonmetastatic with poor histologic response, isolated pulmonary metastases, and metastatic disease to sites other than the lungs. Patients with nonmetastatic disease but poor histologic response after six cycles of vincristine, ifosfamide, doxorubicin, and etoposide were randomized to vincristine, actinomycin, and ifosfamide consolidation chemotherapy or high-dose therapy with busulfan and melphalan with autologous peripheral blood stem cell rescue. The COG participated in this trial, but limited enrollment to patients with pulmonary metastases (under protocol AEWS0031); this cohort randomizes patients to vincristine–doxorubicin–ifosfamide consolidation with whole-lung irradiation or high-dose therapy with busulfan–melphalan and autologous SCT. This study will likely close soon, and results are not yet published.

The morbidity of these intensive chemotherapy-treatment regimens is significant, including therapy-related deaths as well as long-term sequelae. There is thus parallel interest in minimizing toxicity of treatment. Small-molecule-targeted therapies hold promise for improving outcomes with minimal additional toxicity.

The importance of insulin-like growth factor (IGF) signaling in ES has been repeatedly demonstrated in molecular biology investigations, and thus there was significant excitement among ES clinicians and researchers upon the development of clinical IGF 1 receptor (IGF1R) inhibitors.34,55–59 A subset of patients appears to benefit from IGF1R inhibition, but among the general ES population, efficacy is unimpressive. A phase II Sarcoma Alliance for Research through Collaboration (SARC) trial of R1507 (an anti-IGF1R monoclonal antibody that is no longer in clinical development) reported an underwhelming 10% overall response rate.60 Twenty-two adult patients (age range 20–77 years) were enrolled in a Phase II trial of the monoclonal anti-IGF1R antibody ganitumab (AMG479), which demonstrated a median progression-free survival of 7.9 months (95% confidence interval 5.4–25.6 months).61 Over 40% experienced partial response or stabilization of disease, and two patients had prolonged benefit (partial response or stable disease ≥24 weeks). More than 100 patients ages 10–62 years were enrolled in a similar trial to assess the efficacy of the IGF1R antibody figitumumab, but only 14% of patients experienced an objective response.62 A COG Phase I study of single-agent cixutumumab, also a monoclonal anti-IGF1R antibody, included a Phase II expansion cohort for refractory ES (NCT00609141, COG ADVL0712 and NCT00831844, COG ADVL0821). This study had disappointing results for the ES subset, with a progression-free survival of only 44 days.63 Surprisingly, there was also no apparent correlation between tumor expression of IGF1, IGF2, or IGF1R and response to therapy.

A follow-up Phase II combination study of cixutumumab and the mammalian target of rapamycin (mTOR) inhibitor temsirolimus for refractory ES and other sarcomas has not yet reported results (NCT01614795, COG ADVL1221). Preclinical data from the National Cancer Institute (NCI)’s Pediatric Preclinical Testing Program predicts efficacy for this combination in both ES and osteosarcoma, while data from other laboratories questions the utility of targeting IGF1R in ES altogether.64,65 COG will open AEWS1221 in the coming months to define the feasibility of adding ganitumab to interval-compressed VDC/IE for patients with newly diagnosed metastatic ES.66 While the overall response rate to IGF1R inhibitors is disappointing, a few patients have had dramatic responses. Biomarker analysis has been challenging, and has not provided conclusive evidence regarding which patients are likely to respond to IGF1R inhibition. Further biomarker analysis is planned in AEWS1221.

Interest in mTOR has been gathering for years, following the recognition that mTOR signaling plays an important role in ES pathogenesis. Treatment of ES cell lines with rapamycin, the prototypical mTOR inhibitor, results in cell-cycle arrest at G, and downregulation of EWS–FLI1.67 The aforementioned Phase II study of concurrent IGF1R and mTOR inhibition was based on preclinical data supporting this combination approach. Pediatric Preclinical
Testing Program studies of rapamycin demonstrated only intermediate efficacy against ES xenografts when used alone, but were more promising when used together with cixutumumab or vincristine.\textsuperscript{64-68} Seven patients with refractory ES were enrolled in COG ADVL0918, a Phase II trial of temsirolimus in combination with irinotecan and temozolomide.\textsuperscript{70} One patient sustained an objective response for more than 10 months, while another experienced stable disease for several months.

Poly(adenosine diphosphate ribose) polymerase (PARP)-1 is the small-molecule target drawing the most attention currently in the preclinical realm. PARP-1 is an enzyme important for base-excision repair as well as a key ETS protein-family cofactor, a mechanism first discovered in \textit{ETS} fusion-positive prostate carcinomas.\textsuperscript{71} Inhibition of PARP-1 results in decreased anchorage-independent growth and invasion (by in vitro soft-agar colony formation and Boyden transwell experiments) in cell lines expressing \textit{EWS–ETS} fusions.\textsuperscript{72} In mouse xenograft models, the PARP-1 inhibitor olaparib slowed tumor growth when given as monotherapy, but when given in combination with temozolomide resulted in immediate tumor regression and sustained complete response, which is nearly unheard of in models of this disease.\textsuperscript{72} These dramatic results were not replicated in a similar experiment from another laboratory, although response was still seen.\textsuperscript{73} This combination approach is currently being investigated in a Phase I trial (NCT01858168, the upcoming SARC025), and the COG will likely incorporate a PARP inhibitor into the next Phase II trial for relapsed ES.

**Future treatments**

Despite the widely held belief that such transcription-factor fusion-protein targets as \textit{EWS–FLI1} are “undruggable”, additional promising therapies are on the horizon. High-throughput screening techniques have identified two in particular: mithramycin and YK-4-279.

Mithromycin is a nonspecific antineoplastic antibiotic that cross-links guanine–cytosine-rich chromatin regions and prevents hypermethylation, resulting in altered gene transcription.\textsuperscript{74-78} It was used clinically in the 1960s–1970s, including in some cases of ES, and has recently been resurrected.\textsuperscript{79,80} A group of researchers at the NCI reported impressive inhibition of \textit{EWS–FLI1} downstream targets and significant in vivo (xenograft) tumor response with mithramycin, and the NCI subsequently opened a Phase II trial of mithramycin monotherapy in EWS–FLI1-positive ES (NCT01610570).\textsuperscript{81}

While the pathognomonic fusion protein in ES was characterized decades ago, no drug specific to this target has successfully been developed. Erkizan et al have identified the most promising candidate to date, a compound that blocks the binding of ribonucleic acid helicase A to the EWS–FLI1 protein and therefore interferes with its oncogenic function.\textsuperscript{82} YK-4-279 is an optimized derivative of a molecule identified through a surface plasmon-resonance screen of 3,000 small molecules in the NCI Drug Targeting Program library. This compound demonstrates single enantiomer efficacy and minimal toxicity in preclinical animal models, both facts that support the eventual advancement of YK-4-279 into clinical trials.\textsuperscript{83} Subsequently, this group used a similar process combined with phage display to identify the peptide ESAP1, which potently binds to and inhibits EWS–FLI1.\textsuperscript{84} Therapeutic peptides, such as ESAP1, are not yet optimized for clinical use due to stability issues, but will likely be in clinical trials within the next decade.

**Conclusion**

ES is a rare tumor that occurs most frequently in AYAs, and is characterized by disruption of the \textit{EWSR1} gene. Diagnosis and treatment require the involvement of multidisciplinary teams at specialized centers. Outcomes for localized disease are good, with 5-year EFS $>70\%$ for children. There is evidence that AYAs have similar outcomes when treated according to pediatric regimens. Nonetheless, long-term survivors have significant treatment-related morbidity. Current clinical trials aim to define the optimal treatment for metastatic disease, while preclinical research and early phase trials are investigating several promising new targeted agents.

**Acknowledgments**

The authors wish to thank Drs Atiya Mansoor, Phil Raess, and Don Sauser for providing clinical images.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

Clinical Oncology in Adolescents and Young Adults 2014:4


